Development of a model based on body composition to predict drug kinetics-1 evaluation in healthy volunteers

Pharmacological Research

Volumn 50, Issue 1, 2004, Pages 99-104

  Pazzucconi, F ^a   Ferrara, S ^a   Bondioli, A ^a   Zoppi, F ^b   Yeates, R ^c   De Rosa, C ^b   Mombelli, G ^a   Calabresi, L ^a   Sirtori, C R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c PFIZER INC   (United States)

Author keywords

Amlodipine; Body composition; Digoxin; Impedance method; Kinetic modeling; MEGX; Tobramycin

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; DIGOXIN; PHENAZONE; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ELIMINATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMPEDANCE; KIDNEY CLEARANCE; LABORATORY TEST; LINEAR REGRESSION ANALYSIS; LIVER CLEARANCE; LIVER MICROSOME; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NORMAL HUMAN; PHARMACOKINETIC MODEL; PHYSICAL MODEL; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ALGORITHMS; AMLODIPINE; ANESTHETICS, LOCAL; ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BODY COMPOSITION; BODY WATER; CARDIOTONIC AGENTS; DIGOXIN; ELECTRIC IMPEDANCE; HALF-LIFE; HUMANS; INTRACELLULAR FLUID; LIDOCAINE; MODELS, BIOLOGICAL; PHARMACOKINETICS; TOBRAMYCIN;

EID: 1842635491     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.12.009     Document Type: Article

References (34)

1. Jelliffe R., Schumitzky A., Bayard D., Milman M.M.et al. Model-based, goal-oriented, individualized drug therapy. Clin. Pharmacokinet. 34:1998;57-77.
2. Baumgartner R.N., Chumlea W.C., Roche A.F. Bioelectric impedance phase angle and body composition. Am. J. Clin Nutr. 48:1998;16-23.
3. Mahmood I. Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J. Pharm. Pharmacol. 51:1999;905-910.
4. Fliser D., Bischoff I., Hanses A., Block S., Joest M., Ritz E.et al. Renal handling of drugs in the healthy elderly. Eur. J. Clin. Pharmacol. 55:1999;205-211.
5. Yurchak A.M., Franklin B.A. Theophylline disposition in obesity. Clin. Pharmacol. Ther. 23:1978;438-444.
6. Abernethy D.R., Greenblatt D.J. Drug disposition in obese humans an update. Clin Pharmacokinet. 11:1986;199-213.
7. Abernethy D.R., Greenblatt D.J., Divoll M., Harmatz J.S., Shader R.I. Alterations in drug distribution and clearance due to obesity. J. Pharmacol. Exp. Ther. 217:1981;681-685.
8. Abernethy D.R., Schwartz J.B. Pharmacokinetics of calcium antagonists under development. Clin Pharmacokinet. 15:1998;1-14.
9. Haria M., Wagstaff A.J. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 50:1995;560-586.
10. Van Zwieten P.A. Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. Clin. Cardiol. 17:1994;13-16.
11. Hui J., Wang Y.M., Chandrasekaran A., Geraets D.R., Caldwell J.H., Robertson L.W.et al. Disposition of tablet and capsule formulations of digoxin in the elderly. Pharmacotherapy. 14:1994;607-612.
12. Brogden R.N., Pinder R.M., Sawyer P.R., Speight T.M., Avery G.S. Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs. 12:1987;166-200.
13. Lukaski H.C., Johnson P.E., Bolonchuk W.W., Lykken G.I. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am. J. Clin. Nutr. 41:1985;810-817.
14. Diem K, Seldrup J. Scientific tables Geigy. CIBA-GEIGY; 1984.
15. Alvan G., Bechtel P., Iselius L., Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39:1990;533-537.
16. Spina E., Campo G.M., Avenoso A., Caputi A.P., Zuccaro P., Pacifici R.et al. CYP2D6-related oxidation polymorphism in Italy. Pharmacol. Res. 29:1994;281-289.
17. Francis Lam Y.W., Banerji S., Hatfield C., Talbert R.L. Principles of drug administration in renal insufficiency. Clin. Pharmacokinet. 32:1997;30-57.
18. Robieux I., Sorio R., Borsatti E., Cannizzaro R., Vitali V., Aita P.et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin. Pharm. Ther. 59:1996;32-40.
19. Pazzucconi F., Malavasi B., Galli G., Franceschini G., Calabresi L., Sirtori C.R. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clin. Pharmacol. Ther. 49:1991;278-284.
20. Danhof M., De Groot-Van der Vis E., Breimer D.D. Assays of antipyrine and its primary metabolites in plasma, saliva and urine by HPLC, and some preliminary results in man. Pharmacology. 18:1979;210-223.
21. Oellerich M., Raude E., Burdelski M.et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin. Chem. Clin. Biochem. 25:1987;845-853.
22. Zoppi F., Fumagalli C. Improved measurement of MEGX in serum with the Abbott TDx. Clin. Chem. 38:1992;441-442.
23. Brainbridge A.D., Herlihy O., Meredith P.A., Elliot H.L. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur. J. Clin. Pharmacol. 45:1993;425-430.
24. Aronson J.K. Indications for the measurement of plasma digoxin concentrations. Drugs. 26:1983;230-242.
25. Mangione A., Schentag J.J. Therapeutic monitoring of aminoglycoside antibiotics: an approach. Ther. Drug Monit. 2:1980;159-167.
26. Kushner R.F., Schoeller D.A. Estimation of total body water by bioelectrical impedance analysis. Am. J. Clin. Nutr. 44:1986;417-424.
27. Wagner J. Fundamentals of clinical pharmacology. Drug Intelligence Publications; 1979.
28. Tanaka E., Breimer D.D. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J. Clin. Pharm. Therapeut. 22:1987;237-249.
29. Engel G., Hofmann U., Heidemann H., Cosme J., Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 59:1996;613-623.
30. Groen K., Breimer D.D. Antipyrine, theophylline, and hexobarbital as in vivo P450 probe drugs. Methods Enzymol. 272:1996;169-177.
31. Utter A.C., Nieman D.C., Ward A.N., Butterworth D.E. Use of the leg-to-leg bioelectrical impedance method in assessing body-composition change in obese women. Am. J. Clin. Nutr. 69:1999;603-607.
32. Jakicic J.M., Wing R., Lang W. Bioelectrical impedance analysis to assess body composition in obese adult women: the effect of ethnicity. Int. J. Obesity Related. Metab. Disorders. 22:1998;243-249.
33. Baumgartner R.N., Ross R., Heymsfield S.B. Does adipose tissue influence bioelectric impedance in obese men and women? J. Appl. Physiol. 84:1998;257-262.
34. Sjoqvist F. The past, present and future of clinical pharmacology. Eur. J. Clin. Pharmacol. 55:1999;553-557.